Sarah Hughes before adult stem cell therapy (left) at 83 pounds and after (right) at 125 pounds. Hughes was one of three Celltex clients who addressed the FDA at a two-day hearing on the regulation of stem cell therapy in 2016 and will be a special guest at the State of the Union later this month.
Sarah Hughes, a resident of Fulshear, was once planning her own funeral, but now she is planning on being a guest at the State of the Union Address. She spent the first 22-years of her life suffering from systemic juvenile idiopathic arthritis until one day she decided to try a life-changing adult stem cell therapy made possible by a Houston-based biotechnology firm, Celltex Therapeutics. At the time of her first stem cell therapy, Sarah had only a few months to live and weighed a mere 83 pounds. Simply speaking took immense energy. After a lifetime in hospitals and years researching the best possible medical treatments and medications available for her condition, Sarah is a new woman. She’s now riding horses, is engaged to be married and will be a special guest of Texas Congressman Pete Olson (TX-22) at the State of the Union address on February 28, 2017, to represent the promise of the 21st Century Cures Act and adult stem cell innovation in Houston.
Sarah is an involved advocate of stem cell therapies especially for those suffering from dysautonomia. She was one of three Celltex clients to address the U.S. Food and Drug Administration in September 2016, sharing personal testimony of how stem cell therapy, using adult stem cells isolated, extracted and expanded by Celltex, improved her quality of life beyond expectation. Months later, the 21st Century Cures Act was signed into law, thanks to bipartisan support from elected officials like Congressman Olson, who dedicated his vote in favor of the bill in honor of Sarah.
As one of the first commercial stem cell companies in the United States, Celltex’s laboratory uses proprietary technology, which isolates, multiplies and banks autologous (one’s own) adult mesenchymal stem cells (MSCs) in quantities never before possible, to be used for regenerative high-dose adult stem cell therapy. Celltex is registered with the FDA as an HCT/P establishment that multiplies human cells and cellular products. The company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the FDA for the manufacturing of biological products.